Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials

Ergun, Y.Kalkan, Z.Ileri, S.Tunc, S.Urakci, Z.2024-04-242024-04-2420220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.03.203https://hdl.handle.net/11468/15131European-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress -- MAY 03-05, 2022 -- Berlin, GERMANY[Abstract Not Available]eninfo:eu-repo/semantics/openAccess[No Keyword]Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trialsEfficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trialsConference Object33S212S212WOS:00079249410018710.1016/j.annonc.2022.03.203Q1